Journals / Dahili ve Cerrahi Bilimler Yoğun Bakım Dergisi / 2018 / Cilt: 9 - Sayı: 2

Investigation of the Effects of Blood Product Replacement and Type on Mortality in Patients with Sepsis and Septic Shock

Sepsis ve Septik Şok Tanısı ile Takip Edilen Hastalarda Kan Ürünü Replasman Sıklığı ve Türünün Mortalite Üzerine Etkisinin İncelenmesi

Pages
40–45
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The mortality was higher in patients transfused blood and blood products.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Anaemia, thrombocytopenia, leucopenia, disseminated intravascular coagulation (DIC) and functional deficiencies of coagulation factors are all common in patients with severe sepsis or septic shock.
📊
Key Findings & Data:Material and Methods: This prospective descriptive study was performed on patients who are 18 years of age and over, with septic/septic shock who stay for 48 hours or more in the intensive care unit.
💡
Conclusion & Impact:The mortality was higher in patients transfused blood and blood products.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Anaemia, thrombocytopenia, leucopenia, disseminated intravascular coagulation (DIC) and functional deficiencies of coagulation factors are all common in patients with severe sepsis or septic shock. There is no standard protocol for blood and blood product transfusion for this disease. The aim of this study is to evaluate prospectively the blood and blood products transfusion in patients who are diagnosed with sepsis and septic shock. Material and Methods: This prospective descriptive study was performed on patients who are 18 years of age and over, with septic/septic shock who stay for 48 hours or more in the intensive care unit. Results: One hundred three patients were enrolled in this study. Fifty six percent of the patients were male and fourty four percent were female. The mean age was 60.9±17.2 years. APACHE II score of the patients was 23.2±4.1. Patients were included in study in 6 (1-22) hours after being diagnosed with sepsis or septic shock in the intensive care unit. Patients were monitored for 6 (3-26) days as sepsis or septic shock. Blood and blood products was transfused to the 67 patients (65%). The most frequent transfused blood product was red blood cell suspension and the second most frequent transfused blood product was platelet suspension. Red blood cell suspension was transfused to 56% of the patients. The pre-transfusion Hb values of patients transfused erythrocyte suspension was 8.6±1.5 g/dL. A total of 167 units of red blood cell suspension were transfused. Hemoglobin decrease was the most common cause of red blood cell transfusion. A part of 94.8% patients who received red blood cell transfusion died. The mortality rate was statistically higher in the group of red blood cell transfusion compared to the group without transfusion (p=0.005). Platelet suspension was transfused to 30% of the patients. The pre-transfusion platelet values of patients transfused platelet suspension was 23000 (6000-191000) 103 /µL. A total of 163 units of platelet suspension were transfused. Thrombocytopenia was the most common cause of platelet transfusion. All of patients who received platelet transfusion died. Patients mortality rate was 86% in intensive care unit. Conclusion: Patients with sepsis and septic shock who are followed up in intensive care unit are transfused high percent blood and blood products. The most transfused blood products were red blood cell and platelet suspensions. The mortality was higher in patients transfused blood and blood products.

Özet

vasküler koagülasyon (DIC), koagulasyon faktörlerininfonksiyonel eksiklikleri septik şok ve ciddi sepsisde sıklıklagörülmektedir. Bu hastalara kan ve kan ürünü verilmesi ileilgili standart bir protokol bulunmamaktadır. Bu çalışmanınamacı sepsis ve septik şok tanıları ile takip edilen hastalaraverilen kan ve kan ürünlerinin prospektif olarak değerlendirilmesidir.Gereç ve Yöntemler: Bu prospektif tanımlayıcı çalışmaya15.08.2016- 15.04.2017 tarihleri arasında medikal yoğunbakım ünitesinde takip edilen, 18 yaş ve üzeri, YBÜ’nde 48saat ve daha uzun süre tetkik ve tedavi edilmiş, sepsis/septikşoktaki hastalar, kendilerinin veya birinci derece yakınlarınınonamı alındıktan sonra dahil edildi.Bulgular: Çalışmaya 103 hasta alındı. Hastaların %56’ sı erkek,%44’ ü kadındı. Hastaların yaş ortalaması 60,9±17,2 yılidi. Ortalama APACHE II (Acute Physiology and Chronic HealthEvaluation II) skoru 23,2±4,1 idi. Hastalar, YBÜ’ nde yatıpsepsis veya septik şok tanısı aldıktan medyan 6 (range:1-22)saat içinde çalışmaya alındı. Hastalar medyan 6 (range:3-26)gün boyunca sepsis veya septik şok tanılarıyla takip edildi.Çalışmaya alınan hastaların 67’sine (%65) kan ve kan ürünütransfüzyonu yapıldı. En sık verilen kan ürünü eritrositsüspansiyonu (ES), ikinci sık verilen kan ürünü ise trombositsüspansiyonu (TS) idi. Transfüzyon yapılan hastaların %56’ sına ES verildi. Transfüzyon öncesi ortalama Hb değeri8,6±1,5 g/dL idi. Toplam 167 ünite ES transfüzyonu yapıldı.En sık ES replasmanı nedeni hemoglobin düşüklüğü idi. EStransfüzyonu alan hastaların %94,8’ i kaybedildi. ES transfüzyonuyapılan grupta mortalite yapılmayan gruba göredaha yüksekti (p=0.005). Transfüzyon yapılan hastaların%30’ una TS transfüzyonu yapıldı. TS transfüzyonu yapılanhastaların transfüzyon öncesi bakılan trombosit değerlerimedyan 23000 103 /µL (range: 6000-191000 103 /µL) idiToplam 163 ünite TS verildi. Hastalara en sık trombositopeni (163 kez ) nedeniile TS transfüzyonu yapıldı. TS transfüzyonu yapılan hastaların tümü kaybedildi.Çalışmaya alınan hastaların yoğun bakım mortalitesi %86 idi.Sonuç: Yoğun bakım ünitesinde takip edilen sepsis ve septik şok hastalarına yüksekoranda kan ve kan ürünü verilmektedir. Kan ve kan ürünü verilen hastalardamortalite daha yüksek olarak tespit edildi.

🔖

Cite This Article

GÜNDOĞAN, K., SUNGUR, M., TEMEL, Ş., ŞİMŞEK, Z., DİRİK, H., SAVAŞ, N., YÜCESOY, F. S., KARACA, Z., MENDİL, N. Ö. A., ONUK, S., YÜKSEL, R. C., YILDIZ, Ş., BULUT, K. (2022). Investigation of the Effects of Blood Product Replacement and Type on Mortality in Patients with Sepsis and Septic Shock. Dahili ve Cerrahi Bilimler Yoğun Bakım Dergisi, Cilt: 9 - Sayı: 2, 40–45. https://ajindex.com/articles/486525

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Murthy T. Blood transfusion practices in sepsis. Indian J Anaesth 2014
  2. [CrossRef] Rosland RG, Hagen MU, Haase N, Holst LB, Plambech M, Madsen KR, et al. Red blood cell transfusion in septic shock - clinical characteristics and outcome of unselected patients in a prospective, multicentre cohort. Scand J Trauma Resusc Emerg Med 2014
  3. [CrossRef] Practice parameters for hemodynamic support of sepsis in adult patients in sepsis. Task Force of the American College of Critical Care Medicine, Society of Critical Care Medicine. Crit Care Med 1999
  4. [CrossRef] Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013
  5. [CrossRef] Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001
  6. [CrossRef] Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Crit Care Med 2017
  7. [CrossRef] Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Abraham E, et al. The CRIT Study: Anemia and blood transfusion in the critically ill--current clinical practice in the United States. Crit Care Med 2004
  8. [CrossRef] Holst LB, Haase N, Wetterslev J, Wernerman J, Aneman A, Guttormsen AB, et al. Transfusion requirements in septic shock (TRISS) trial - comparing the effects and safety of liberal versus restrictive red blood cell transfusion in septic shock patients in the ICU: protocol for a randomised controlled trial. Trials. 2013
  9. [CrossRef] Holst LB, Haase N, Wetterslev J, Wernerman J, Aneman A, Guttormsen AB, et al. Transfusion requirements in septic shock (TRISS) trial - comparing the effects and safety of liberal versus restrictive red blood cell transfusion in septic shock patients in the ICU: protocol for a randomised controlled trial. Trials 2013
  10. [CrossRef] Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999
  11. [CrossRef] Marik PE, Corwin HL. Efficacy of red blood cell tra